Moderna outlines $80B market

Posted 3 April 2024 AM

Moderna has vaccines in development to take on a combined $80 billion (US$52 billion) market for infectious diseases, the mRNA giant told its fifth annual Vaccines and Business Update, and although it might be late to the RSV party, it's thrown down the gauntlet to rivals.

Over half of the company's vaccine market, $42 billion (US$27 billion), is for respiratory vaccines including Covid, the vaccine Moderna has on the market, while latent and other vaccines address the remaining $40 billion.

To see the whole article, please login